B-NHL 2013 B-NHL 2013 - Behandlungsprotokoll der NHL-BFM und der NOPHO-Studiengruppen für reife aggressive B-Zell-Lymphome und -Leukämien bei Kindern und Jugendlichen (Aktiv)
CZAR-1 fficacy and safety of Carfilzomib in combination with Ibrutinib for patients with Waldenström's macroglobulinemia (CZAR-1) (Aktiv)
JCAR017-BCM-004 JE A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) (Aktiv)
M22-132 A study to evaluate adverse events and change in disease activity of subcutaneous (SC) epcoritamab in combination with oral and intravenous anti-neoplastic agents in adult participants with Non-Hodgkin Lymphoma Phase 1b/2, open-label study to evaluate safety and tolerability of Epcoritamab in combination with anti-neoplastic agents in subjects with Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic Agents (Aktiv)
POLE-1 Efficacy of pembrolizumab in patients with marginal zone lymphoma (Aktiv)
TRANSCENDWORLD Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma (TRANSCENDWORLD) (Aktiv)
Erstlinie
NHL 3-2004 Therapy Optimisation for the Treatment of Hairy Cell Leukemia (Aktiv)
Zweitlinie oder später
67856633LYM1001 A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)
CHARLY Study on the value of post-transplant Cyclophosphamide after Thiotepa-based haplo-identical stem-cell transplantation for relapsed-refractory lymphoma (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
CVOB560A12101 A Phase Ib, Multicenter Study of VOB560 in Combination With MIK665 in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma. (Aktiv)
GC-LTFU-001 Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells (Aktiv)
Lymrit-37-01 A Phase I/II Study of Lutetium (177Lu)-Lilotomab Satetraxetan (Betalutin®) Antibody-radionuclide-conjugate for Treatment of Relapsed Non-Hodgkin Lymphoma. (Aktiv)
R1979-ONC-1625 Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (Aktiv)
REGN1979-HM-1333 This is an open-label, multi-center, dose escalation study of REGN1979 administered as an IV (intravenous) infusion. This phase 1 study will investigate the safety and tolerability of REGN1979 in patients with Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) (Aktiv)